首页 > 最新文献

Revista Espa?ola de Enfermedades Metabólicas óseas最新文献

英文 中文
Desarrollo y validaci n de un cuestionario predictivo de osteoporosis (OPARG score) 骨质疏松症预测问卷(OPARG评分)的开发和验证
Pub Date : 2006-06-01 DOI: 10.1016/S1132-8460(06)75259-X
D.A. Pate, O.D. Messina

Introducción

Se encuentran descritos múltiples factores de riesgo (FR) asociados a la osteoporosis. Evaluamos la capacidad predictiva, individual y colectiva de los mismos. El trabajo consta de dos fases sucesivas; inicialmente se desarrolló un modelo predictivo y luego se validó prospectivamente.

Materiales y métodos

Se construyó un cuestionario de FR y se interrogó a las mujeres que participaron antes de realizar absorciometría dual de rayos X (DEXA). Se diseñó un modelo predictivo y se aplicó en una nueva población.

Resultados

Fase inicial: 785 mujeres (osteoporosis: 26,11%). La edad, postmenopausia, datos antropométricos y antecedentes de fracturas demostraron ser los FR más relevantes. El modelo es aplicable a mujeres postmenopáusicas. Fase de validación: 502 pacientes postmenopáusicas (osteoporosis: 27,49%). Se puso de manifiesto una correlación significativa entre lo observado en la población estudiada y lo predicho por el modelo.

Conclusión

Una puntuación mayor o igual a 3 es indicación de realizar un procedimiento diagnóstico. Este método puede utilizarse para optimizar la selección de pacientes de mayor riesgo.

Introduction

Several risk factors (RF) have been associated to the development of osteoporosis. We have evaluated the predictive capacity of many of them in two phases. Initially we developed a predictive score and then we validated the model prospectively.

Material and methods

A questionnaire on RF was designed. The women were questioned prior to performing a bone mineral density measurement by DXA. A predictive score was designed. This was applied to a new population.

Results

During the first phase 785 women were included. 26.11% of them were diagnosed as having osteoporosis according to the WHO definition. Age, postmenopausal state, personal history of fracture and weight were shown to be the most relevant RF. The score is applicable to postmenopausal women.

Validation phase 502 postmenopausal women (osteoporosis: 27.49%) were included. A significant correlation was observed between that observed in the population studied and that predicted by the score.

Conclusion

A score ≥ 3 warranted performing a diagnostic procedure. This method may be used to optimize identifying patients at high risk.

本文描述了与骨质疏松症相关的多种危险因素(FR)。我们评估他们个人和集体的预测能力。这项工作包括两个连续的阶段;首先开发了一个预测模型,然后进行了前瞻性验证。本研究的目的是评估一项随机对照试验(rct)的有效性,该试验旨在评估一名女性在接受双X射线吸收仪(DEXA)之前的rf问卷调查。设计了一个预测模型,并将其应用于一个新的群体。结果初始阶段:785名女性(骨质疏松症:26.11%)。年龄、绝经后、人体测量数据和骨折史是最相关的。该模型适用于绝经后妇女。验证阶段:502例绝经后患者(骨质疏松症:27.49%)。在研究人群中观察到的结果与模型预测的结果之间存在显著的相关性。结论得分大于或等于3表示需要进行诊断程序。该方法可用于优化高危患者的选择。一些危险因素(RF)与骨质疏松症的发展有关。我们分两个阶段评估了许多预测能力。首先,我们开发了一个预测评分,然后对模型进行了前瞻性验证。设计了射频问卷的材料和方法。= =地理= =根据美国人口普查局的数据,该镇总面积为,其中土地和(1.1%)水。= =地理= =根据美国人口普查局的数据,该县总面积为,其中土地和(1.)水。这适用于一个新的人口。在第一阶段,785名女性被包括在内。根据世卫组织的定义,26.11%的人被诊断为骨质疏松症。年龄、绝经后状况、个人骨折史和体重被认为是最相关的。该分数适用于绝经后的女性。包括绝经后502期妇女(骨质疏松症:27.49%)的验证。在研究人群中观察到的结果与得分预测的结果之间存在显著相关性。完成≥3分保证执行诊断程序。该方法可用于优化高危患者的识别。
{"title":"Desarrollo y validaci n de un cuestionario predictivo de osteoporosis (OPARG score)","authors":"D.A. Pate,&nbsp;O.D. Messina","doi":"10.1016/S1132-8460(06)75259-X","DOIUrl":"10.1016/S1132-8460(06)75259-X","url":null,"abstract":"<div><h3>Introducción</h3><p>Se encuentran descritos múltiples factores de riesgo (FR) asociados a la osteoporosis. Evaluamos la capacidad predictiva, individual y colectiva de los mismos. El trabajo consta de dos fases sucesivas; inicialmente se desarrolló un modelo predictivo y luego se validó prospectivamente.</p></div><div><h3>Materiales y métodos</h3><p>Se construyó un cuestionario de FR y se interrogó a las mujeres que participaron antes de realizar absorciometría dual de rayos X (DEXA). Se diseñó un modelo predictivo y se aplicó en una nueva población.</p></div><div><h3>Resultados</h3><p>Fase inicial: 785 mujeres (osteoporosis: 26,11%). La edad, postmenopausia, datos antropométricos y antecedentes de fracturas demostraron ser los FR más relevantes. El modelo es aplicable a mujeres postmenopáusicas. Fase de validación: 502 pacientes postmenopáusicas (osteoporosis: 27,49%). Se puso de manifiesto una correlación significativa entre lo observado en la población estudiada y lo predicho por el modelo.</p></div><div><h3>Conclusión</h3><p>Una puntuación mayor o igual a 3 es indicación de realizar un procedimiento diagnóstico. Este método puede utilizarse para optimizar la selección de pacientes de mayor riesgo.</p></div><div><h3>Introduction</h3><p>Several risk factors (RF) have been associated to the development of osteoporosis. We have evaluated the predictive capacity of many of them in two phases. Initially we developed a predictive score and then we validated the model prospectively.</p></div><div><h3>Material and methods</h3><p>A questionnaire on RF was designed. The women were questioned prior to performing a bone mineral density measurement by DXA. A predictive score was designed. This was applied to a new population.</p></div><div><h3>Results</h3><p>During the first phase 785 women were included. 26.11% of them were diagnosed as having osteoporosis according to the WHO definition. Age, postmenopausal state, personal history of fracture and weight were shown to be the most relevant RF. The score is applicable to postmenopausal women.</p><p>Validation phase 502 postmenopausal women (osteoporosis: 27.49%) were included. A significant correlation was observed between that observed in the population studied and that predicted by the score.</p></div><div><h3>Conclusion</h3><p>A score ≥ 3 warranted performing a diagnostic procedure. This method may be used to optimize identifying patients at high risk.</p></div>","PeriodicalId":101109,"journal":{"name":"Revista Espa?ola de Enfermedades Metabólicas óseas","volume":"15 3","pages":"Pages 39-43"},"PeriodicalIF":0.0,"publicationDate":"2006-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1132-8460(06)75259-X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122915460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factores que influyen en el cumplimiento terap utico en la osteoporosis 影响骨质疏松症治疗依从性的因素
Pub Date : 2006-06-01 DOI: 10.1016/S1132-8460(06)75260-6
N. Guañabens

El cumplimiento terapéutico es un reto en la práctica clínica. Así, en los últimos años se ha evidenciado que los pacientes con enfermedades crónicas como la osteoporosis tienen un bajo cumplimiento de la medicación recomendada. Recientemente se han identificado los factores que influyen en el cumplimiento, destacando aspectos sociales y económicos, factores relacionados con la enfermedad de base y con el propio tratamiento, y por último con las características del paciente. En este artículo se revisan estos aspectos, con el interés de ofrecer una visión global de los factores implicados en el bajo cumplimiento terapéutico en la osteoporosis.

Compliance with drug therapies is a key point in clinical practice. In the last years, awareness about the poor compliance with medications in chronic disorders such as osteoporosis has emerged. In addition, most factors that influence compliance with prescribed medications have been identified. They include social and economic aspects, illness and treatment related factors as well as patient characteristics. This article is focused on data concerning the factors responsible for poor compliance with drug therapies in osteoporosis.

治疗依从性是临床实践中的一个挑战。因此,近年来,骨质疏松等慢性疾病患者对推荐药物的依从性较低。最近确定了影响依从性的因素,突出了社会和经济方面,与基础疾病和治疗本身有关的因素,最后是患者的特点。然而,在许多情况下,治疗依从性较低的因素可能与治疗依从性较低的因素有关,而治疗依从性较低的因素可能与治疗依从性有关。= =地理= =根据美国人口普查,这个县的面积为,其中土地和(1.1%)水。在过去的几年里,人们对骨质疏松等慢性疾病的药物依从性差的认识已经出现。此外,已经确定了影响遵守处方药物的大多数因素。它们包括社会和经济方面、疾病和治疗相关因素以及病人特征。这篇文章的重点是关于导致骨质疏松症药物治疗依从性差的因素的数据。
{"title":"Factores que influyen en el cumplimiento terap utico en la osteoporosis","authors":"N. Guañabens","doi":"10.1016/S1132-8460(06)75260-6","DOIUrl":"10.1016/S1132-8460(06)75260-6","url":null,"abstract":"<div><p>El cumplimiento terapéutico es un reto en la práctica clínica. Así, en los últimos años se ha evidenciado que los pacientes con enfermedades crónicas como la osteoporosis tienen un bajo cumplimiento de la medicación recomendada. Recientemente se han identificado los factores que influyen en el cumplimiento, destacando aspectos sociales y económicos, factores relacionados con la enfermedad de base y con el propio tratamiento, y por último con las características del paciente. En este artículo se revisan estos aspectos, con el interés de ofrecer una visión global de los factores implicados en el bajo cumplimiento terapéutico en la osteoporosis.</p></div><div><p>Compliance with drug therapies is a key point in clinical practice. In the last years, awareness about the poor compliance with medications in chronic disorders such as osteoporosis has emerged. In addition, most factors that influence compliance with prescribed medications have been identified. They include social and economic aspects, illness and treatment related factors as well as patient characteristics. This article is focused on data concerning the factors responsible for poor compliance with drug therapies in osteoporosis.</p></div>","PeriodicalId":101109,"journal":{"name":"Revista Espa?ola de Enfermedades Metabólicas óseas","volume":"15 3","pages":"Pages 44-46"},"PeriodicalIF":0.0,"publicationDate":"2006-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1132-8460(06)75260-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123847633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Efecto de la terapia biol gica sobre el metabolismo seo en las enfermedades inflamatorias articulares 生物治疗对关节炎症性疾病seo代谢的影响
Pub Date : 2006-06-01 DOI: 10.1016/S1132-8460(06)75263-1
M.V. Hernández
{"title":"Efecto de la terapia biol gica sobre el metabolismo seo en las enfermedades inflamatorias articulares","authors":"M.V. Hernández","doi":"10.1016/S1132-8460(06)75263-1","DOIUrl":"https://doi.org/10.1016/S1132-8460(06)75263-1","url":null,"abstract":"","PeriodicalId":101109,"journal":{"name":"Revista Espa?ola de Enfermedades Metabólicas óseas","volume":"15 3","pages":"Pages 52-54"},"PeriodicalIF":0.0,"publicationDate":"2006-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1132-8460(06)75263-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92139219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Osteonecrosis de la cabeza femoral 股骨头骨坏死
Pub Date : 2006-06-01 DOI: 10.1016/S1132-8460(06)75261-8
E. González Reimers , M. Arnay de la Rosa , J. Velasco-Vázquez
{"title":"Osteonecrosis de la cabeza femoral","authors":"E. González Reimers ,&nbsp;M. Arnay de la Rosa ,&nbsp;J. Velasco-Vázquez","doi":"10.1016/S1132-8460(06)75261-8","DOIUrl":"10.1016/S1132-8460(06)75261-8","url":null,"abstract":"","PeriodicalId":101109,"journal":{"name":"Revista Espa?ola de Enfermedades Metabólicas óseas","volume":"15 3","pages":"Pages 47-48"},"PeriodicalIF":0.0,"publicationDate":"2006-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1132-8460(06)75261-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121668196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Special report on the official positions of the international society for clinical densitometry 关于国际临床密度测定学会官方立场的特别报告
Pub Date : 2006-06-01 DOI: 10.1016/S1132-8460(06)75262-X
M.J. Peña Millán
{"title":"Special report on the official positions of the international society for clinical densitometry","authors":"M.J. Peña Millán","doi":"10.1016/S1132-8460(06)75262-X","DOIUrl":"10.1016/S1132-8460(06)75262-X","url":null,"abstract":"","PeriodicalId":101109,"journal":{"name":"Revista Espa?ola de Enfermedades Metabólicas óseas","volume":"15 3","pages":"Pages 49-51"},"PeriodicalIF":0.0,"publicationDate":"2006-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1132-8460(06)75262-X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121746607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Inhibidores de la aromatasa y osteoporosis 芳香化酶抑制剂和骨质疏松症
Pub Date : 2006-06-01 DOI: 10.1016/S1132-8460(06)75264-3
X. Nogués I Solán
{"title":"Inhibidores de la aromatasa y osteoporosis","authors":"X. Nogués I Solán","doi":"10.1016/S1132-8460(06)75264-3","DOIUrl":"https://doi.org/10.1016/S1132-8460(06)75264-3","url":null,"abstract":"","PeriodicalId":101109,"journal":{"name":"Revista Espa?ola de Enfermedades Metabólicas óseas","volume":"15 3","pages":"Pages 55-56"},"PeriodicalIF":0.0,"publicationDate":"2006-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1132-8460(06)75264-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92091028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Osteoporosis en medicina interna. Ha sido til el estudio cosmis? 内科骨质疏松症。这是cosmis工作室吗?
Pub Date : 2006-04-01 DOI: 10.1016/S1132-8460(06)75254-0
J. Calvo Catalá , J.J. García-Borrás , C. Campos Fernández , A. Baixauli Rubio , M. Muñoz Guillém , M.I. González-Cruz , J.L. Valero Sanz

Introducción

La osteoporosis, a pesar de ser la enfermedad metabólica ósea más frecuente, está infradiagnosticada y, por tanto, infratratada.

Pacientes y métodos

Para conocer la situación en que se encontraba esta patología en los servicios de Medicina Interna, en el año 2003, se desarrolló el proyecto COSMIS (Conocimiento de la Osteoporosis en los Servicios de Medicina Interna SEIOMM), estudio que confirmó los datos esperados, con un diagnóstico de osteoporosis en pacientes mayores de 60 años de un 3,4%. Sólo un 3,1% recibía tratamiento correcto.

Resultados

Dos años después, hemos revalorado los mismos parámetros en dos hospitales que intervinieron en el primer estudio, obteniendo unos resultados semejantes. A pesar de los numerosos factores de riesgo detectados en los pacientes y de las fracturas vertebrales reseñadas, la osteoporosis sigue estando poco diagnosticada y poco tratada.

Conclusiones

Nuevos estudios, grupos de trabajo, etc., pueden contribuir a mejorar esta situación, siendo importante la colaboración de las autoridades sanitarias mediante planes que apoyen esta enfermedad tan prevalente y con tan importantes consecuencia socioeconómicas.

Introduction

In spite of being the most frequent metabolic disease, osteoporosis is under-diagnosed and under-treated.

Patients and methods

The COSMIS project (Knowledge of Osteoporosis in Internal Medicine Services SEIOMM) was developed in 2003 in order to know osteoporosis patterns in Internal Medicine Services. This study confirmed the expected data, with a 3.4% diagnosis of osteoporosis in those over 60 years of age. Only 3.1% were receiving correct treatment.

Results

Two years later, we reevaluated the same parameters in two Hospitals that participated in the first study, obtaining similar results. In spite of the many risk factors detected in the patients and of the vertebral fractures reviewed, osteoporosis continues to be under-diagnosed and under-treated. The small relationship with the many risk factors detected and even with the vertebral fractures is striking.

Conclusions

Our studies, work groups, etc. may contribute to improve this situation, collaboration of the regulatory authorities by plans that support such a prevalent disease with such important socioeconomic consequences being important.

骨质疏松症虽然是最常见的代谢性骨疾病,但诊断不足,因此治疗不足。病人和métodosPara情势在这个病理内科服务,在2003年开发了COSMIS项目(了解骨质疏松内科SEIOMM)服务,确认了预期的数据,其中60岁以上的骨质疏松症患者诊断3.4%。只有3.1%的人得到了正确的治疗。两年后,我们在参与第一项研究的两家医院重新评估了相同的参数,得到了相似的结果。尽管在患者中发现了许多危险因素,并报告了椎体骨折,骨质疏松症仍然很少被诊断和治疗。结论:新的研究、工作组等可能有助于改善这种情况,卫生当局通过支持这一具有重大社会经济后果的普遍疾病的计划进行合作是很重要的。尽管骨质疏松症是最常见的代谢疾病,但诊断和治疗不足。患者和方法COSMIS项目(在内科医疗服务中了解骨质疏松症)是在2003年开发的,目的是了解内科医疗服务中骨质疏松症的模式。该研究证实了预期数据,60岁以上人群中有3.4%的人患有骨质疏松症。只有3.1%的人得到了正确的治疗。两年后,我们在参与第一次研究的两家医院重新评估了相同的参数,得到了相似的结果。尽管在患者中发现了许多危险因素,并对椎体骨折进行了回顾,但骨质疏松症仍未得到充分诊断和治疗。与检测到的许多风险因素,甚至与椎体骨折的关系都很小。结论研究、工作组等可能有助于改善这种情况,监管当局通过支持这种具有重大社会经济后果的普遍疾病的计划进行合作。
{"title":"Osteoporosis en medicina interna. Ha sido til el estudio cosmis?","authors":"J. Calvo Catalá ,&nbsp;J.J. García-Borrás ,&nbsp;C. Campos Fernández ,&nbsp;A. Baixauli Rubio ,&nbsp;M. Muñoz Guillém ,&nbsp;M.I. González-Cruz ,&nbsp;J.L. Valero Sanz","doi":"10.1016/S1132-8460(06)75254-0","DOIUrl":"10.1016/S1132-8460(06)75254-0","url":null,"abstract":"<div><h3>Introducción</h3><p>La osteoporosis, a pesar de ser la enfermedad metabólica ósea más frecuente, está infradiagnosticada y, por tanto, infratratada.</p></div><div><h3>Pacientes y métodos</h3><p>Para conocer la situación en que se encontraba esta patología en los servicios de Medicina Interna, en el año 2003, se desarrolló el proyecto COSMIS (Conocimiento de la Osteoporosis en los Servicios de Medicina Interna SEIOMM), estudio que confirmó los datos esperados, con un diagnóstico de osteoporosis en pacientes mayores de 60 años de un 3,4%. Sólo un 3,1% recibía tratamiento correcto.</p></div><div><h3>Resultados</h3><p>Dos años después, hemos revalorado los mismos parámetros en dos hospitales que intervinieron en el primer estudio, obteniendo unos resultados semejantes. A pesar de los numerosos factores de riesgo detectados en los pacientes y de las fracturas vertebrales reseñadas, la osteoporosis sigue estando poco diagnosticada y poco tratada.</p></div><div><h3>Conclusiones</h3><p>Nuevos estudios, grupos de trabajo, etc., pueden contribuir a mejorar esta situación, siendo importante la colaboración de las autoridades sanitarias mediante planes que apoyen esta enfermedad tan prevalente y con tan importantes consecuencia socioeconómicas.</p></div><div><h3>Introduction</h3><p>In spite of being the most frequent metabolic disease, osteoporosis is under-diagnosed and under-treated.</p></div><div><h3>Patients and methods</h3><p>The COSMIS project (Knowledge of Osteoporosis in Internal Medicine Services SEIOMM) was developed in 2003 in order to know osteoporosis patterns in Internal Medicine Services. This study confirmed the expected data, with a 3.4% diagnosis of osteoporosis in those over 60 years of age. Only 3.1% were receiving correct treatment.</p></div><div><h3>Results</h3><p>Two years later, we reevaluated the same parameters in two Hospitals that participated in the first study, obtaining similar results. In spite of the many risk factors detected in the patients and of the vertebral fractures reviewed, osteoporosis continues to be under-diagnosed and under-treated. The small relationship with the many risk factors detected and even with the vertebral fractures is striking.</p></div><div><h3>Conclusions</h3><p>Our studies, work groups, etc. may contribute to improve this situation, collaboration of the regulatory authorities by plans that support such a prevalent disease with such important socioeconomic consequences being important.</p></div>","PeriodicalId":101109,"journal":{"name":"Revista Espa?ola de Enfermedades Metabólicas óseas","volume":"15 2","pages":"Pages 21-23"},"PeriodicalIF":0.0,"publicationDate":"2006-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1132-8460(06)75254-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131818475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Es posible la comparaci n de f rmacos head to head en osteoporosis? 是否有可能对骨质疏松症进行面对面的药物比较?
Pub Date : 2006-04-01 DOI: 10.1016/S1132-8460(06)75258-8
X. Nogués y Solán
{"title":"Es posible la comparaci n de f rmacos head to head en osteoporosis?","authors":"X. Nogués y Solán","doi":"10.1016/S1132-8460(06)75258-8","DOIUrl":"https://doi.org/10.1016/S1132-8460(06)75258-8","url":null,"abstract":"","PeriodicalId":101109,"journal":{"name":"Revista Espa?ola de Enfermedades Metabólicas óseas","volume":"15 2","pages":"Pages 37-38"},"PeriodicalIF":0.0,"publicationDate":"2006-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1132-8460(06)75258-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91633011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Los fitoestr genos como agentes moduladores del metabolismo seo 植物甾醇基因作为seo代谢调节剂
Pub Date : 2006-04-01 DOI: 10.1016/S1132-8460(06)75257-6
A.R. de Gortázar
{"title":"Los fitoestr genos como agentes moduladores del metabolismo seo","authors":"A.R. de Gortázar","doi":"10.1016/S1132-8460(06)75257-6","DOIUrl":"10.1016/S1132-8460(06)75257-6","url":null,"abstract":"","PeriodicalId":101109,"journal":{"name":"Revista Espa?ola de Enfermedades Metabólicas óseas","volume":"15 2","pages":"Pages 34-36"},"PeriodicalIF":0.0,"publicationDate":"2006-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1132-8460(06)75257-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130678151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tratamiento de la osteoporosis en la mujer premenop usica 女性绝经前骨质疏松症的治疗
Pub Date : 2006-04-01 DOI: 10.1016/S1132-8460(06)75256-4
P. Peris
{"title":"Tratamiento de la osteoporosis en la mujer premenop usica","authors":"P. Peris","doi":"10.1016/S1132-8460(06)75256-4","DOIUrl":"https://doi.org/10.1016/S1132-8460(06)75256-4","url":null,"abstract":"","PeriodicalId":101109,"journal":{"name":"Revista Espa?ola de Enfermedades Metabólicas óseas","volume":"15 2","pages":"Pages 30-33"},"PeriodicalIF":0.0,"publicationDate":"2006-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1132-8460(06)75256-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91633013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Revista Espa?ola de Enfermedades Metabólicas óseas
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1